

Research Study Opportunity:

Adults with Non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS)

The goal of this Phase 3 clinical trial is to demonstrate the efficacy and safety of frexalimab compared to placebo in adult participants with nrSPMS to delay disability progression.

Who can take part in the study?

You, or someone you care for, may be able to take part if you/they:

- Are 18-60 years old
- Have a previous diagnosis of RRMS
- Have a current diagnosis of SPMS with documented disability progression within the past 12 months
- Have an EDSS of 3.0 - 6.0
- Have an absence of relapses in the past 24 months

Additional Study Details

- This study will have variable duration ranging from approximately 27 to 51 months, depending on enrollment date.
- The number of scheduled visits will be up to 27 (including 3 follow-up visits) with a visit frequency of every month for the first 6 months and then every 3 months.
- Participants will receive a stipend for each visit as well as travel reimbursement.



Study Location:

Minnesota Center for
Multiple Sclerosis

15700 37th Ave N, Suite 110
Plymouth, MN 55446